Clinical Trial Detail

NCT ID NCT03665129
Title IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Innate Pharma
Indications

Advanced Solid Tumor

Therapies

Durvalumab + IPH5401

Age Groups: adult senior

Additional content available in CKB BOOST